Christopher Downs - 22 Aug 2023 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
23 Aug 2023, 08:00:04 UTC
Prior SEC filing
01 May 2023
Next SEC filing
06 Feb 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Christopher Downs

Key filing fact

Christopher Downs filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 23 Aug 2023.

Key facts

  • This page summarizes Christopher Downs's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 23 Aug 2023, 08:00.

Change

  • Previous filing in this sequence was filed on 01 May 2023.
  • Current net transaction value: +$34,177.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNSP transaction

Common Stock

Purchase

Transaction value
$34,177
Shares
+27,000
Change %
+276%
Price
$1.27
Shares after
36,772
Date
22 Aug 2023
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This transaction was executed in multiple trades at prices ranging from $1.2196 to $1.2999. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .